Rho kinase inhibitors: a patent review (2014 – 2016)

References

• Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. Embo J. 1996;15:2208–2216.
   PubMed Web of Science ®Google Scholar
• Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996;392:189–193.
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298:1912−34.
   PubMed Web of Science ®Google Scholar
• Feng Y, LoGrasso PV, Defert O, et al. Rho kinase (ROCK) inhibitors and their therapeutic potential. J Med Chem. 2016;59:2269−300.
   PubMed Web of Science ®Google Scholar
• Loirand G. Rho kinases in health and disease: from basic science to translational research. Pharmacol Rev. 2015;67:1074–1095.
   PubMed Web of Science ®Google Scholar
• Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol. 2011;7:657–671.
   PubMedGoogle Scholar
• Hartmann S, Ridley AJ, Lutz S. The function of Rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease. Front Pharmacol. 2015;6:276.
   PubMed Web of Science ®Google Scholar
• Sardana M, Moll M, Farber HW. Novel investigational therapies for treating pulmonary arterial hypertension. Expert Opin Investig Drugs. 2015;24:1571–1596.
   PubMed Web of Science ®Google Scholar
• Donegan RK, Lieberman RL. Discovery of molecular therapeutics for glaucoma: challenges, successes and promising directions. J Med Chem. 2016;59:788–809.
   PubMed Web of Science ®Google Scholar
• Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res. 2016 September 1. 2016: published online. DOI:10.1016/j.exer.2016.08.023
   Google Scholar
• Albersen M, Shindel AW, Mwamukonda KB, et al. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerging Drugs. 2010;15:467−80.
   PubMed Web of Science ®Google Scholar
• Wei L, Surma M, Shi S, et al. Novel insights into the roles of Rho kinase in cancer. Arch Immunol Ther Exp. 2016;64:259–278.
   PubMed Web of Science ®Google Scholar
• Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Reports. 2012;13:900–908.
   PubMed Web of Science ®Google Scholar
• Huang Y, Xiao S, Jiang Q. Role of Rho kinase signal pathway in inflammatory bowel disease. Int J Clin Exp Med. 2015;8:3089–3097.
   PubMed Web of Science ®Google Scholar
• Knipe RS, Tager AM, Liao JK. The rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67:103–117.
   PubMed Web of Science ®Google Scholar
• Holvoet T, Devriese S, Castermans K, et al. Soft rock inhibition prevents intestinal fibrosis in a murine colitis model. Gastroenterology, Meeting Abstract, 46th Annual Digestive Disease Week, Washington DC, 2016
   Google Scholar
• Shaw D, Hollingworth G, Soldermann N, et al. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension. Bioorg Med Chem Lett. 2014;24:4812−7.
   PubMed Web of Science ®Google Scholar
• Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Visual Sci. 2007;48:3216−22.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;128:309−15.
   Google Scholar
• DeLong MA, Sturdivant JM, Royalty S, et al. Discovery and in vitro SAR of AR-12286, a potent kinase inhibitor for the treatment of glaucoma. Investigative ophthalmology & visual science, meeting abstract. Rockville, MD: The Association for Research in Vision and Ophthalmology; 2009.
   Google Scholar
• Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667−77.
   PubMedGoogle Scholar
• Richards L, Crean CS, Peterson WM, et al. Ophthalmic formulation of rho kinase inhibitor compound. WO2009155209 (2009)
   Google Scholar
• Peterson WM, Lampe J, Navratil T, et al. Topical administration of a novel and potent Rho kinase (ROK) inhibitor INS117548 alters the actin cytoskeleton, effectively lowers IOP, and is well tolerated on the ocular surface. Rockville, MD: Investigative Ophthalmology & Visual Science, Meeting Abstract; The Association for Research in Vision and Ophthalmology; 2008.
   Google Scholar
• Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74:2211−15.
   PubMed Web of Science ®Google Scholar
• Bacharach J, Dubiner HB, Levy B, et al. AR-13324-CS202 study group. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122:302−7.
   PubMed Web of Science ®Google Scholar
• Levy B, Ramirez N, Novack GD, et al. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159:980−985.
   PubMed Web of Science ®Google Scholar
• Wang RF, Williamson JE, Kopczynski C, et al. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24:51−4.
   PubMed Web of Science ®Google Scholar
• Van De Velde S, Van Bergen T, Sijnave D, et al. AMA0076, a novel, locally acting rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Visual Sci. 2014;55:1006−16.
   PubMed Web of Science ®Google Scholar
• Feng Y, LoGrasso PV. Rho kinases inhibitors: a patent review (2012-2013). Expert Opin Ther Patents. 2014;24:295–307.
   PubMed Web of Science ®Google Scholar
• Curtin ML, Sorensen BK, Heyman HR, et al. NAMPT and ROCK inhibitors. WO2012067965 (2012)
   Google Scholar
• Lampe JW, Watson PS, Vittitow JL, et al. Bifunctional Rho kinase inhibitor compounds composition and use. WO2012012282 (2012)
   Google Scholar
• Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK) structure, regulation and functions. Small Gtpases. 2014;5:e29846.
   PubMedGoogle Scholar
• Defert O, Boland S. Kinase profiling in early stage drug discovery: sorting things out. Drug Disc. Today: Technologies.. 2015;18:52–61.
   PubMedGoogle Scholar
• Campbell S, Foudoulakis H, Kirk B, et al. Preparation of 4-[(1H-indazol-5-yl)amino]quinazolines as ROCK1 and/or ROCK2 kinase inhibitors with improved pharmacokinetic properties. WO2006105081 (2006)
   Google Scholar
• Lee JH, Zheng Y, Von Bornstadt D, et al. Selective ROCK2 inhibition in focal cerebral ischemia. Ann Clin Transl Neurol. 2014;1:2–14.
   PubMed Web of Science ®Google Scholar
• Flynn R, Paz K, Du J, et al. Targeted rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127:2144–2154.
   PubMed Web of Science ®Google Scholar
• Yiu ZZ, Warren RB. Novel oral therapies for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2016;17:191–200.
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorox A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111:16814–16819.
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Kim J, Liu K, et al. Rho kinase inhibitors. WO2014055996 (2014).
   Google Scholar
• Kim J, Liu K, Poyurovsky M, et al. Rho kinases inhibitors. WO2015054317 (2015).
   Google Scholar
• Glick G. 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties. WO2011062765 (2011).
   Google Scholar
• Aicher TD, Padilla F, Toogood PL, et al. Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and treatment of disease. WO2016138335 (2016)
   Google Scholar
• Lampe JW, Shavre SR, Watson PS. Method for treating ophthalmic diseases using kinase inhibitor compound in prodrug forms. WO2012015760 (2012)
   Google Scholar
• Leysen D, Defert O, Kaval N, et al. Preparation of heterocyclic amides as ROCK inhibitors. WO2011107608 (2011)
   Google Scholar
• Boland S, Defert O, Alen J, et al. 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Bioorg Med Chem Lett. 2013;23:6442–6446.
   PubMed Web of Science ®Google Scholar
• Hall J, Sall KN, Peace JH, et al. Initial clinical evaluation of safety, tolerability and pharmacodynamics of the locally-acting ROCK inhibitor AMA0076. Orlando, FL: Investigative Ophthalmology & Visual Science, Meeting Abstract; The Association for Research in Vision and Ophthalmology; 2014.
   Google Scholar
• Hollanders K, Van Bergen T, Kindt N, et al. The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56:1335–1348.
   PubMed Web of Science ®Google Scholar
• Boland S, Bourin A, Alen J, et al. Design, synthesis and biological evaluation of novel, highly active soft ROCK inhibitors. J Med Chem. 2015;58:4309–4324.
   PubMed Web of Science ®Google Scholar
• Bourin A, Leysen D, Defert O, et al. Preparation of substituted amides as novel ROCK inhibitors. WO2014068035 (2014)
   Google Scholar
• Boland S, Bourin A, Defert O, et al. Prepn. of pyridine derivs. that are soft ROCK inhibitors useful in treatment and prevention of diseases. WO2014118133 (2014)
   Google Scholar
• Takami A, Iwakubo M, Okada Y, et al. Design and synthesis of Rho kinase inhibitors (I). Bioorg Med Chem Lett. 2004;12:2115–37.
   Web of Science ®Google Scholar
• Iwakubo M, Takami A, Okada Y, et al. Design and synthesis of Rho kinase inhibitors (II). Bioorg Med Chem Lett. 2007;15:350–64.
   Web of Science ®Google Scholar
• Iwakubo M, Takami A, Okada Y, et al. Design and synthesis of Rho kinase inhibitors (III). Bioorg Med Chem Lett. 2007;15:1022–33.
   Web of Science ®Google Scholar
• Lampe JW, Watson PS, Slade DJ, et al. Cytoskeletal active Rho kinase inhibitor compounds, composition and use. WO2008/077057 (2008).
   Google Scholar
• Leysen D, Defert O, Boland S, et al. Preparation of isoquinolinyl-aminopiperidinyl-methylbenzoate derivatives and analogs for use as ROCK inhibitors. WO2012146724 (2012)
   Google Scholar
• Procopiou PA, Biggadike K, English AF, et al. Novel glucocorticoid antedrugs possessing a 17beta-(gamma-lactone) ring. J Med Chem. 2001;44:602–612.
   PubMed Web of Science ®Google Scholar
• Holvoet T, Devriese S, Castermans K, et al. Treatment of intestinal fibrosis in experimental inflammatory bowel disease via the pleiotropic actions of a local Rho kinase inhibitor. Gastroenterology. Submitted.
   Google Scholar
• Wu L, Yao Y, Chen Z, et al. Isoquinolinesulfonyl derivative as Rho kinase inhibitor. WO2015165341 (2015).
   Google Scholar
• Wu L, Yao Y, Chen Z, et al. Isoquinolinesulfonamide derivative, and pharmaceutical composition, and pharmaceutical use thereof. WO2015165342 (2015).
   Google Scholar
• Islam I, Johns A, Mylecraine L, et al. Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine. WO2004106325 (2004)
   Google Scholar
• Lawrence N, Pireddu R, Sebti SM Pyridinethiazole-based ureas as inhibitors of Rho associated kinase (ROCK) and methods of use. WO2011130740 (2011).
   Google Scholar
• Lawrence N, Sebti SM, Pireddu R. Novel Rho kinase inhibitors and methods of use. WO2012135697 (2012).
   Google Scholar
• Schonbrunn E, Li R, Sebti SM. Inhibitors of Rho Associated Protein Kinases (ROCK) and Methods of Use. WO2013112722 (2013).
   Google Scholar
• Pireddu R, Forinash KD, Sun NN, et al. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Med Chem Commun. 2012;3:699–709.
   Web of Science ®Google Scholar
• Patel RA, Forinash KD, Pireddu R, et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012;72:5025–5034.
   PubMed Web of Science ®Google Scholar
• Chimenti S, Courchay C, Dessinges A. Derivatives of 5-Benzylisoquinoline for the Treatment of Cardiovascular Diseases. WO2015124877 (2015).
   Google Scholar
• Glunz PW, Zou Y, Quan ML, et al. Phthalazinones et isoquinolinones as ROCK inhibitors. WO2014113620 (2014).
   Google Scholar
• Quan ML, Hu Z, Wang C, et al. Tricyclic pyridocarboxamide derivatives as ROCK inhbitors. WO2015002915 (2015).
   Google Scholar
• Quan ML, Hu Z, Wang C. Tricyclic pyridocarboxamide derivatives as ROCK inhbitors. WO2015002926 (2015).
   Google Scholar
• Liong Z Hexahydro-azepine oxy-benzamide compounds serving as Rho kinase inhibitor. CN104803914 (2015)
   Google Scholar
• Schwartz RJ, Zhang H, Craft JW. Rho Associated Kinase (ROCK) Inhibitors and Their Use in treating Disease. WO2016057306 (2016).
   Google Scholar
• Segain JP, Raingeard De La Blétière D, Sauzeau V, et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn’s disease and experimental colitis. Gastroenerology. 2003;124:1180–7.
   PubMed Web of Science ®Google Scholar
• De Saint Basile G, Fischer A, Bigorgne A, RhoA (ROCK) inhibitors for the treatment of inflammatory bowel disease. WO2014177699 (2014).
   Google Scholar
• Lingor P, Tonges L. Rho kinase inhibitors for use in treating amyotropic lateral sclerosis. WO2013135596 (2013).
   Google Scholar
• McKerracher L, Bond LM. Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors. US20160213664 (2016).
   Google Scholar
• Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–4.
   PubMed Web of Science ®Google Scholar
• Papadatos-Pastos D, Kumar R, Yap TA, et al. A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers. Am Soc Clin Oncology, Annu Meet (ASCO). J Clin Oncol 33, 2015; (suppl; abstr 2566).
   Google Scholar
• Yoshimi E, Kumakura F, Hatori C, et al. Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis. J Pharmacol Exp Ther. 2010;334:955–963.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:26–34.
   PubMed Web of Science ®Google Scholar
• Aerie Pharmaceuticals [cited 10 October 2016] Available from: http://investors.aeriepharma.com/releases.cfm
   Google Scholar
• Rodansky E, Liu X, Johnson LA, et al. Anti-fibrotic therapy for Crohn’s disease: in vitro proof of concept with a selective ROCK2 inhibitor, LYC-53976, in the treatment of human intestinal myofibroblasts in stiffness and transforming growth factor β model. European Crohn’s and Colitis Organization (ECCO).  Abstract P068, 2016.
   Google Scholar
• Zandi S, Nakao S, Chun KH, et al. ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. Cell Reports. 2015;10:1173–1186.
   PubMed Web of Science ®Google Scholar